Eli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDA
Results from a phase III study with diabetes drug Jardiance are so promising that that the FDA has granted the medication breakthrough designation for fast tracking.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
The US Food and Drug Administration (FDA) has designated the drug Jardiance from Eli Lilly and Boehringer Ingelheim the status 'breakthrough,' which fasttracks the application of the substance against a special type of heart failure, Eli Lilly informs in a statement. The FDA further explains the special status with the promising results from a phase III trial with Jardiance in the above indication.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
